Preview

Кардиология

Расширенный поиск

Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии

https://doi.org/10.18087/cardio.2021.2.n1348

Полный текст:

Аннотация

В обзоре рассмотрены основные причины и факторы риска смерти пациентов c фибрилляцией предсердий (ФП). Проанализированы современные терапевтические стратегии ведения пациентов с ФП с точки зрения их влияния на прогноз и показатели смертности. Уделено особое внимание стратегии контроля ритма, клинической важности метода катетерной абляции в лечении пациентов с ФП и сердечной недостаточностью.

 

Об авторах

А. В. Ардашев
ФГБОУ ВО «Московский государственный университет им. М. В. Ломоносова», Москва
Россия
д.м.н, профессор


Ю. Н. Беленков
ФГБОУ ВО «Московский государственный университет им. М. В. Ломоносова», Москва
Россия
академик РАН, д.м.н., профессор


М. Ч. Матюкевич
УО «Гродненский государственный медицинский университет», Гродно
Беларусь
врач-кардиолог


Виктор Александрович Снежицкий
УО «Гродненский государственный медицинский университет», Гродно
Беларусь
чл.-корр. НАНБ, д.м.н., профессор


Список литературы

1. Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A, S B et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. EP Europace. 2020;22(8):1147–8. DOI: 10.1093/europace/euaa065

2. Rattanawong P, Upala S, Riangwiwat T, Jaruvongvanich V, Sanguankeo A, Vutthikraivit W et al. Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis. Journal of Interventional Cardiac Electrophysiology. 2018;51(2):91–104. DOI: 10.1007/s10840-017-0308-9

3. Jani BD, Nicholl BI, McQueenie R, Connelly DT, Hanlon P, Gallacher KI et al. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. EP Europace. 2018;20(FI_3):f329–36. DOI: 10.1093/europace/eux322

4. Eisen A, Ruff CT, Braunwald E, Nordio F, Corbalán R, Dalby A et al. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial. Journal of the American Heart Association. 2016;5(7):e003735. DOI: 10.1161/JAHA.116.003735

5. Tose Costa Paiva B, Fischer TH, Brachmann J, Busch S. Catheter ablation of atrial fibrillation-A key role in heart failure therapy? Clinical Cardiology. 2019;42(3):400–5. DOI: 10.1002/clc.23150

6. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2019;74(1):104–32. DOI: 10.1016/j.jacc.2019.01.011

7. Waldmann V, Jouven X, Narayanan K, Piot O, Chugh SS, Albert CM et al. Association Between Atrial Fibrillation and Sudden Cardiac Death: Pathophysiological and Epidemiological Insights. Circulation Research. 2020;127(2):301–9. DOI: 10.1161/CIRCRESAHA.120.316756

8. Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlöf B et al. Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy. Circulation: Arrhythmia and Electrophysiology. 2013;6(2):243–51. DOI: 10.1161/CIRCEP.112.977777

9. Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández A-I, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2016;68(23):2508–21. DOI: 10.1016/j.jacc.2016.09.944

10. Matta M, Saglietto A, De Salvo P, Bissolino A, Ballatore A, Anselmino M. Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure? Herz. 2019;44(3):218– 22. DOI: 10.1007/s00059-019-4794-7

11. Jagadish PS, Kabra R. Stroke Risk in Atrial Fibrillation: Beyond the CHA2DS2-VASc Score. Current Cardiology Reports. 2019;21(9):95. DOI: 10.1007/s11886-019-1189-6

12. Long S, Xi Y, Gao L, Chen Q, Cheng J, Yang Y et al. Safety and efficacy of catheter ablation in atrial fibrillation patients with left ventricular dysfunction. Clinical Cardiology. 2020;43(3):305–14. DOI: 10.1002/clc.23314

13. Modin D, Claggett B, Gislason G, Hansen ML, Worck R, Johannessen A et al. Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death. EP Europace. 2020;22(1):74–83. DOI: 10.1093/europace/euz264

14. Smer A, Salih M, Darrat YH, Saadi A, Guddeti R, Mahfood Haddad T et al. Meta-analysis of randomized controlled trials on atrial fibrillation ablation in patients with heart failure with reduced ejection fraction. Clinical Cardiology. 2018;41(11):1430–8. DOI: 10.1002/clc.23068

15. Burkman G, Naccarelli GV. Rhythm Control of Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports. 2020;22(9):83. DOI: 10.1007/s11886-020-01336-8

16. Бубешко Д.А., Снежицкий В.А. К вопросу о механизмах развития тахииндуцированной кардиомиопатии у пациентов с фибрилляцией предсердий. Журнал Гродненского государственного медицинского университета. 2015;2(50):24-9

17. Ma Y, Bai F, Qin F, Li Y, Tu T, Sun C et al. Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders. 2018;18(1):165. DOI: 10.1186/s12872-018-0904-3

18. Снежицкий В.А., Бубешко Д.А. Роль воспаления в патогенезе фибрилляции предсердий. Кардиология в Беларуси. 2015;4(41):129-38

19. Dzeshka MS, Lip GYH, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2015;66(8):943–59. DOI: 10.1016/j.jacc.2015.06.1313

20. Baher A, Marrouche NF. Management of Atrial Fibrillation in Patients with Heart Failure: Time to Implement Ablation Control. Current Cardiology Reports. 2019;21(2):10. DOI: 10.1007/s11886-019-1093-0

21. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. 2016;5(6):e003725. DOI: 10.1161/JAHA.116.003725

22. Noseworthy PA, Van Houten HK, Gersh BJ, Packer DL, Friedman PA, Shah ND et al. Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm. 2020;17(7):1057–65. DOI: 10.1016/j.hrthm.2020.02.030

23. Black-Maier E, Ren X, Steinberg BA, Green CL, Barnett AS, Rosa NS et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm. 2018;15(5):651– 7. DOI: 10.1016/j.hrthm.2017.12.001

24. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261–74. DOI: 10.1001/jama.2019.0693

25. Jarman JWE, Hussain W, Wong T, Markides V, March J, Goldstein L et al. Resource use and clinical outcomes in patients with atrial fibrillation with ablation versus antiarrhythmic drug treatment. BMC Cardiovascular Disorders. 2018;18(1):211. DOI: 10.1186/s12872-018-0946-6

26. Kheirkhahan M, Marrouche NF. It is time for catheter ablation to be considered a first-line treatment option in patients with atrial fibrillation and heart failure. Heart Rhythm. 2018;15(5):658–9. DOI: 10.1016/j.hrthm.2018.02.009

27. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016;133(17):1637–44. DOI: 10.1161/CIRCULATIONAHA.115.019406

28. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction. Journal of the American College of Cardiology. 2017;70(16):1949–61. DOI: 10.1016/j.jacc.2017.08.041

29. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. New England Journal of Medicine. 2018;378(5):417–27. DOI: 10.1056/NEJMoa1707855

30. Terricabras M, Verma A. Stopping oral anticoagulation after successful ablation for atrial fibrillation: reality or fiction? EP Europace. 2019;22(1):euz284. DOI: 10.1093/europace/euz284

31. Saksena S, Slee A. Atrial fibrillation and its pernicious role in heart failure with preserved ejection fraction: a new frontier in interventional electrophysiology. Journal of Interventional Cardiac Electrophysiology. 2018;51(2):89–90. DOI: 10.1007/s10840-018-0341-3

32. Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clinical Cardiology. 2020;43(2):145–55. DOI: 10.1002/clc.23321

33. Adabag S, Langsetmo L. Sudden cardiac death risk prediction in heart failure with preserved ejection fraction. Heart Rhythm. 2020;17(3):358–64. DOI: 10.1016/j.hrthm.2019.12.009

34. Black-Maier E, Steinberg BA, Trulock KM, Wang F, Lokhnygina Y, O’Neal W et al. Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. Journal of Arrhythmia. 2020;36(1):84–92. DOI: 10.1002/joa3.12291


Для цитирования:


Ардашев А.В., Беленков Ю.Н., Матюкевич М.Ч., Снежицкий В.А. Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии. Кардиология. 2021;61(2):91-98. https://doi.org/10.18087/cardio.2021.2.n1348

For citation:


Ardashev A.V., Belenkov Yu.N., Matsiukevich M.C., Snezhitskiy V.A. Atrial Fibrillation and Mortality: Prognostic Factors and Direction of Prevention. Kardiologiia. 2021;61(2):91-98. (In Russ.) https://doi.org/10.18087/cardio.2021.2.n1348

Просмотров: 376


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)